KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables (2020 - 2022)

Recursion Pharmaceuticals (RXRX) has disclosed Receivables for 3 consecutive years, with $2.8 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Receivables fell 69.71% year-over-year to $2.8 million, compared with a TTM value of $2.8 million through Dec 2022, down 69.71%, and an annual FY2022 reading of $2.8 million, down 69.71% over the prior year.
  • Receivables was $2.8 million for Q4 2022 at Recursion Pharmaceuticals, down from $11.6 million in the prior quarter.
  • Across five years, Receivables topped out at $11.7 million in Q2 2022 and bottomed at $49000.0 in Q2 2021.
  • Average Receivables over 3 years is $5.5 million, with a median of $2.8 million recorded in 2022.
  • Peak annual rise in Receivables hit 23736.73% in 2022, while the deepest fall reached 69.71% in 2022.
  • Year by year, Receivables stood at $156000.0 in 2020, then surged by 5726.92% to $9.1 million in 2021, then plummeted by 69.71% to $2.8 million in 2022.
  • Business Quant data shows Receivables for RXRX at $2.8 million in Q4 2022, $11.6 million in Q3 2022, and $11.7 million in Q2 2022.